Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Virus Diseases 1Sexually Transmitted Diseases 1Papillomavirus Infections 1Keratosis, Actinic 1Condylomata Acuminata 1

Interventions

Aminolevulinic Acid 113-ingenyl angelate 9Photochemotherapy 5Imiquimod 5Fluorouracil 4Petrolatum 3Solutions 2SR-T100 2Gels 2Cryotherapy 2potassium dobesilate 1perillyl alcohol 1endonuclease V, phage T4 1dehydroftorafur 1calcipotriene 1afamelanotide 1Triamcinolone 1Therapies, Investigational 1Papillomavirus Vaccines 1Ointments 1Melatonin 1Lasers 1LEO 43204 1Isotretinoin 1Imipramine 1Excipients 1Eflornithine 1Deoxyribonuclease (Pyrimidine Dimer) 1Cholecalciferol 1Chemexfoliation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Keratosis, Actinic × Therapies, Investigational × Clear all
NCT02404389 2021-01-05

Safety, Tolerability, and Efficacy Study of LFX453 in Actinic Keratosis Patients

Novartis

Phase 2 Completed
82 enrolled 16 charts
Dermatologic

Keratosis, Actinic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡